Therefore, TP53 mutation structural mutant risk groups were more significantly associated with overall survival among breast cancer patients with a TP53 DNA BD MM than progesterone, estrogen or HER2 receptor status, or PAM50 molecular subtype. This evidence concerns the gene TP53 and breast carcinoma.